603079
XSHG
Market cap269mUSD
Nov 20, Last price
9.51CNY
1D
-7.67%
1Q
-32.22%
IPO
-22.01%
Name
Zhejiang Shengda Bio-pharm Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Zhejiang Shengda Bio-Pharm Co., Ltd., based in Tiantai, China, is a global enterprise dedicated to the research, development, manufacturing, and distribution of a diverse range of food and animal feed additives. The company's comprehensive product portfolio includes essential vitamins like biotin and folic acid, biological preservation agents such as nisin and natamycin, and intermediate Active Pharmaceutical Ingredients (APIs). They also provide various natural solutions for food preservation.
Key people
Xiangxiao Xu
Finance Director · since 2022
Chao Liang
General Manager · since 2025
Bin Zhou
General Manager · since 2019
Chaoqun Hong
Deputy General Manager · since 2025
Han Pang
Deputy General Manager · since 2018
Xiao Xie
Deputy General Manager · since 2025
Wei Han
Secretary of the Board · since 2025
Director · since 2013
Bincheng Chu
Staff Elected Director · since 2025
Ai Hong
Chairman of the Board
Jianxin Xu
Deputy General Manager, Director · since 2022
Yonggang Zhu
Director · since 2022
Jing Zhu
Deputy General Manager, Director · since 2019
Yi-Xuan Zhu
Director · since 2025
Guohua Hu
Independent Director
Yongquan Li
Independent Director · since 2021
Independent Director · since 2025
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||